journal
MENU ▼
Read by QxMD icon Read
search

Clinical Lung Cancer

journal
https://www.readbyqxmd.com/read/28189594/addressing-the-palliative-setting-in-advanced-lung-cancer-should-not-remain-a-barrier-a%C3%A2-multicenter-study
#1
Annelies Janssens, Sofie Derijcke, Anneke Lefebure, Elke Vandenbroucke, Veerle Surmont, Dieter Coeman, Daniëlle Galdermans, Ann-Marie Morel, Birgitta I Hiddinga, Jan P van Meerbeeck
BACKGROUND: Implementation of early palliative care (EPC) into daily oncology practice remains difficult. One of the barriers preventing oncologists from starting EPC is open communication about the palliative setting. The aim of this study was to investigate the relevance of this communication barrier. PATIENTS AND METHODS: In this cross-sectional multicenter study, 106 patients with advanced thoracic cancer were issued a questionnaire to survey 3 dimensions of interest: illness understanding, observation of conversation regarding prognosis and end-of-life (EoL) care, and information preferences of the patients...
January 20, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28189593/external-validation-of-a-prognostic-score-for-patients-receiving-palliative-thoracic-radiotherapy-for-lung-cancer
#2
Carsten Nieder, Terje Tollåli, Ellinor Haukland, Anne Reigstad, Liv Randi Flatøy, Astrid Dalhaug
BACKGROUND: Palliative thoracic radiotherapy is a common treatment for patients with incurable lung cancer. A recent study suggested that a prognostic score based on performance status and N and M stage predicts survival and might support decision-making (eg, when deciding about fractionation). Our aim was to perform a validation study in an independent, larger dataset. PATIENTS AND METHODS: This was a retrospective single-institution study of 232 patients with small- or non-small-cell lung cancer, with methodology comparable with that of the original study...
January 19, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28185793/establishment-of-an-adjusted-prognosis-analysis-model-for-initially-diagnosed-non-small-cell-lung-cancer-with-brain-metastases-from-sun-yat-sen-university-cancer-center
#3
Xiao-Xiao Dinglin, Shu-Xiang Ma, Fang Wang, De-Lan Li, Jian-Zhong Liang, Xin-Ru Chen, Qing Liu, Yin-Duo Zeng, Li-Kun Chen
BACKGROUND: The current published prognosis models for brain metastases (BMs) from cancer have not addressed the issue of either newly diagnosed non-small-cell lung cancer (NSCLC) with BMs or the lung cancer genotype. We sought to build an adjusted prognosis analysis (APA) model, a new prognosis model specifically for NSCLC patients with BMs at the initial diagnosis using adjusted prognosis analysis (APA). PATIENTS AND METHODS: The model was derived using data from 1158 consecutive patients, with 837 in the derivation cohort and 321 in the validation cohort...
January 13, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28188101/antiangiogenic-therapy-in-advanced-non-small-cell-lung-cancer-a-meta-analysis-of-phase-iii-randomized-trials
#4
REVIEW
Jacques Raphael, Kelvin Chan, Safiya Karim, Robert Kerbel, Henry Lam, Keemo Delos Santos, Ronak Saluja, Sunil Verma
We conducted a meta-analysis to evaluate the efficacy of adding any antiangiogenic therapy (AT) to the standard of care in advanced non-small-cell lung cancer (NSCLC). The electronic databases Ovid PubMed, Cochrane Central Register of Controlled Trials, and Embase were searched to identify eligible trials. We included all phase III randomized trials with any line and type of treatment, histology. and AT dose. Pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and pooled odds ratio (OR) for overall response rates (RR) were calculated...
January 12, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28185792/randomized-phase-iii-study-of-docetaxel-plus-cisplatin-versus-pemetrexed-plus-cisplatin-as-first-line-treatment-of-nonsquamous-non-small-cell-lung-cancer-a-trail-trial
#5
Cheol-Kyu Park, In-Jae Oh, Kyu-Sik Kim, Yoo-Duk Choi, Tae-Won Jang, Youn-Seup Kim, Kwan-Ho Lee, Kyeong-Cheol Shin, Chi Young Jung, Sei-Hoon Yang, Jeong-Seon Ryu, Seung-Hun Jang, Seung-Soo Yoo, Suk-Joong Yong, Kye Young Lee, Kwang-Ho In, Min-Ki Lee, Young-Chul Kim
INTRODUCTION: To date, no prospective phase III trials have directly compared the efficacy of pemetrexed plus cisplatin (Pem-Cis) with docetaxel plus cisplatin (Doc-Cis) in patients with nonsquamous non-small-cell lung cancer. MATERIALS AND METHODS: A total of 148 chemotherapy-naive patients lacking driver mutations were randomized into 21-day regimens of cisplatin 70 mg/m(2) with either docetaxel 60 mg/m(2) (n = 71) or pemetrexed 500 mg/m(2) (n = 77) for ≤ 4 cycles...
January 11, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28162944/epidermal-growth-factor-receptor-egfr-mutation-in-exon-19-p-e749q-confers-resistance-to-gefitinib-in-one-patient-with-lung-adenocarcinoma
#6
Giovenzio Genestreti, Dario de Biase, Monica Di Battista, Giovanna Cavallo, Roberta Degli Esposti, Michela Visani, Giorgia Acquaviva, Thomas Brand, Annalisa Pession, Giovanni Tallini, Alba A Brandes
No abstract text is available yet for this article.
January 11, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28188100/the-use-of-antiangiogenic-agents-for-lung-cancer-in-elderly-patients-an-expert-panel-discussion-synopsis
#7
Mark A Socinski, Jamie E Chaft, Benjamin Levy, Gregory J Riely, Corey J Langer, Roman Perez-Soler, Deborah L Middleton, Linda Gracie-King, Laura M Healy
No abstract text is available yet for this article.
January 5, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28185791/evolution-of-symptom-burden-of-advanced-lung-cancer-over-a-decade
#8
Mike R Sung, Milan V Patel, Sarvar Djalalov, Lisa W Le, Frances A Shepherd, Ronald L Burkes, Ronald Feld, Stephanie Lin, Roxana Tudor, Natasha B Leighl
INTRODUCTION: Lung cancer is associated with higher levels of symptom distress and unmet needs than other cancer types. We assessed changes in symptoms, function, understanding, and preferences of patients with advanced lung cancer over a 10-year period. MATERIALS AND METHODS: A 26-item self-administered questionnaire was used to assess symptom burden, functional impairment, knowledge of disease and treatment, and information preferences. The survey was administered to consecutive outpatients with advanced lung cancer first in 2002 and a second cohort in 2012...
January 5, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28162946/first-clinical-report-of-proton-beam-therapy-for-postoperative-radiotherapy-for-non-small-cell-lung-cancer
#9
Jill S Remick, Caitlin Schonewolf, Peter Gabriel, Abigail Doucette, William P Levin, John C Kucharczuk, Sunil Singhal, Taine T V Pechet, Ramesh Rengan, Charles B Simone, Abigail T Berman
BACKGROUND AND PURPOSE: The characteristic Bragg peak of proton beam therapy (PBT) allows for sparing normal tissues beyond the tumor volume that may allow for decreased toxicities associated with postoperative radiation therapy (PORT). Here we report the first institutional experience with proton therapy for PORT in patients with non-small-cell lung cancer (NSCLC) and assess early toxicities and outcomes. MATERIALS AND METHODS: We identified 61 consecutive patients treated from 2011 to 2014 who underwent PORT for locally advanced NSCLC for positive microscopic margins and/or positive N2 lymph nodes (stage III), with 27 patients receiving PBT and 34 receiving intensity-modulated radiation therapy (IMRT)...
January 5, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28131635/effect-of-combined-therapy-inhibiting-egfr-and-vegfr-pathways-in-non-small-cell-lung-cancer-on-progression-free-and-overall-survival
#10
Tao Jiang, Meng Qiao, Fei Zhou, Shengxiang Ren, Chunxia Su, Caicun Zhou
BACKGROUND: To investigate the effect of combined epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) receptor (VEGFR) pathway inhibitors on progression-free survival (PFS) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: We included 15 randomized clinical trials that had compared the combination of EGFR tyrosine kinase inhibitors and anti-VEGF/VEGFR therapy with different control groups...
December 29, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28131636/superior-treatment-response-and-in-field-tumor-control-in-epidermal-growth-factor-receptor-mutant-genotype-of-stage-iii-nonsquamous-non-small-cell-lung-cancer-undergoing-definitive-concurrent-chemoradiotherapy
#11
Yu Jin Lim, Ji Hyun Chang, Hak-Jae Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Jin Chul Paeng, Keon Wook Kang, June-Key Chung, Yoon Kyung Jeon, Doo Hyun Chung, Hong-Gyun Wu
BACKGROUND: Although previous in vitro data have suggested a more radio-sensitive nature of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) cell lines, the clinical behavior according to the EGFR mutational status has not been well-established. In this study, we performed a comparative outcome analysis of EGFR-mutant and wild-type locally advanced NSCLC with chemoradiotherapy (CRT). PATIENTS AND METHODS: A total of 102 patients with stage III nonsquamous NSCLC undergoing primary CRT were identified...
December 28, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28111120/real-world-eq5d-health-utility-scores-for-patients-with-metastatic-lung-cancer-by-molecular-alteration-and-response-to-therapy
#12
Catherine Labbé, Yvonne Leung, João Gabriel Silva Lemes, Erin Stewart, Catherine Brown, Andrea Perez Cosio, Mark Doherty, Grainne M O'Kane, Devalben Patel, Nicholas Cheng, Mindy Liang, Gursharan Gill, Alexandra Rett, Hiten Naik, Lawson Eng, Nicole Mittmann, Natasha B Leighl, Penelope A Bradbury, Frances A Shepherd, Wei Xu, Geoffrey Liu, Doris Howell
INTRODUCTION: Economic analyses of upcoming treatments for lung cancer benefit from real-world health utility scores (HUSs) in an era of targeted therapy. METHODS: A longitudinal cohort study at Princess Margaret Cancer Centre evaluated 1571 EQ5D-3L-derived HUSs in 475 outpatients with metastatic lung cancer across various disease states. Patients with epidermal growth factor receptor (EGFR) (n = 183) and anaplastic lymphoma kinase (ALK) (n = 38) driver alterations were enriched through targeted enrolment; patients with wild-type non-small-cell lung cancer (WT NSCLC) (n = 224) and small-cell lung cancer (SCLC) (n = 30) were sampled randomly...
December 28, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28089594/epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-sensitive-exon-19-insertion-and-exon-20-insertion-in-patients-with-advanced-non-small-cell-lung-cancer
#13
Yen-Ting Lin, Yi-Nan Liu, Shang-Gin Wu, James Chih-Hsin Yang, Jin-Yuan Shih
BACKGROUND: The clinical responsiveness to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) patients with exon 19 insertion and the specific exon 20 insertion (A763_Y764 insFQEA) are still not well known. MATERIALS AND METHODS: We analyzed cancer specimens taken from NSCLC patients for EGFR mutations using RNA reverse transcription polymerase chain reaction or direct DNA sequencing. The clinical course and responsiveness to an EGFR TKI in patients with EGFR exon 19 insertion or exon 20 insertion (A763_Y764 insFQEA) were recorded...
December 28, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28082049/evolution-and-increasing-complexity-of-the-therapeutic-landscape-in-advanced-non-small-cell-lung-cancer
#14
David R Gandara, Jonathan W Riess, Karen Kelly, Tianhong Li, Philip C Mack, Primo N Lara
The therapeutic landscape in advanced non-small-cell lung cancer (NSCLC) is rapidly changing. Never have so many changes of major importance occurred within so short a time. The present perspective describes this rapid evolution and resultant increasing complexity in the therapeutic decision-making process for the practicing oncologist.
December 24, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28117221/comparative-effectiveness-and-resource-usage-in-patients-receiving-first-line-taxane-based-chemotherapy-for-stage-iv-non-small-cell-lung-cancer-in-a-us-community-oncology-setting
#15
Jared Weiss, Rex W Force, Brook A Pugmire, Teri Peterson, Claudio Faria, Sandra Margunato-Debay, Manish B Patel
BACKGROUND: Weekly (qw) nanoparticle albumin-bound (nab)-paclitaxel was approved for advanced non-small-cell lung cancer based on the results from a phase III trial in which nab-paclitaxel/carboplatin demonstrated a significantly greater response rate compared with paclitaxel/carboplatin every 3 weeks (q3w). Little information exists on relative real-world results. MATERIALS AND METHODS: The present retrospective study used data from a national electronic medical record database...
December 22, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28111119/ebus-tbna-as-a-promising-method-for-the-evaluation-of-tumor-pd-l1-expression-in-lung-cancer
#16
Rie Sakakibara, Kentaro Inamura, Yuichi Tambo, Hironori Ninomiya, Satoru Kitazono, Noriko Yanagitani, Atsushi Horiike, Fumiyoshi Ohyanagi, Yosuke Matsuura, Masayuki Nakao, Mingyon Mun, Sakae Okumura, Naohiko Inase, Makoto Nishio, Noriko Motoi, Yuichi Ishikawa
BACKGROUND: Because most lung cancers are diagnosed at advanced stages, we are forced to conduct molecular testing using small biopsy samples. Endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) is emerging as a minimally invasive biopsy technique. Here, we examined the usefulness of EBUS-TBNA to evaluate programmed death-ligand 1 (PD-L1) expression in lung cancer. METHODS: Using 97 consecutive cases of lung cancer diagnosed by EBUS-TBNA, from which 20 transbronchial biopsy (TBB) samples were available, we evaluated the number and morphological intactness of tumor cells in EBUS-TBNA and TBB samples...
December 22, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28089158/cardiac-dose-and-survival-after-stereotactic-body-radiotherapy-for-early-stage-non-small-cell-lung-cancer
#17
Amode R Tembhekar, Cari L Wright, Megan E Daly
INTRODUCTION: Recent analyses have identified cardiac dose as an important predictor of overall survival (OS) after chemoradiation for locally advanced non-small-cell lung cancer (NSCLC). However, the survival influence of the cardiac dose after stereotactic body radiotherapy (SBRT) is unknown. We performed a dose-volume histogram (DVH) analysis of patients treated with SBRT for early stage NSCLC to examine survival and cardiac toxicity. MATERIALS AND METHODS: We reviewed the medical records of patients who had undergone SBRT for early-stage NSCLC from June 2007 to June 2015 and documented the cardiac DVH parameters, including the maximum and mean dose and percentage of volume receiving >5, >10, >20, and >30 Gy (V5, V10, V20, and V30, respectively)...
December 22, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28089157/genomic-profiling-of-circulating-tumor-dna-in-relapsed-egfr-mutated-lung-adenocarcinoma-reveals-an-acquired-fgfr3-tacc3-fusion
#18
Justin M Allen, Alexa B Schrock, Rachel L Erlich, Vincent A Miller, Philip J Stephens, Jeffrey S Ross, Sai-Hong Ignatius Ou, Siraj M Ali, Davood Vafai
No abstract text is available yet for this article.
December 22, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28087132/practice-patterns-of-thoracic-radiotherapy-for-extensive-stage-small-cell-lung-cancer-survey-of-us-academic-thoracic-radiation-oncologists
#19
Carl M Post, Vivek Verma, Timur Mitin, Charles B Simone
PURPOSE: Despite the recent CREST trial demonstrating a survival benefit to thoracic radiotherapy (TRT) for patients with extensive-stage small-cell lung cancer (ES-SCLC) with response to chemotherapy, as well as endorsement by current National Comprehensive Cancer Network guidelines, TRT may not be uniformly delivered in clinical practice across all circumstances. METHODS AND MATERIALS: We surveyed US academic thoracic radiation oncologists regarding their practice patterns for TRT and assessed conditions in which withholding TRT could be warranted...
December 22, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28073681/association-of-cytoplasmic-cxcr4-with-loss-of-epithelial-marker-and-activation-of-erk1-2-and-akt-signaling-pathways-in-non-small-cell-lung%C3%A2-cancer
#20
Nabil F Saba, Yuxiang Wang, Hongpeng Fu, Lydia Koenig, Fadlo R Khuri, Dong M Shin, Zhuo Georgia Chen
OBJECTIVES: Compelling evidence demonstrates that CXC-chemokine receptor 4 (CXCR4) is involved in tumor invasion, angiogenesis, metastasis, and resistance to chemotherapy in addition to being one of the coreceptors for T-tropic human immunodeficiency virus entry into T cells. However, it remains controversial as to how to identify functionally activated CXCR4 in tumor biopsies, which would assist in determining which patients may benefit from potential CXCR4-targeted therapy. MATERIALS AND METHODS: Immunohistochemistry (IHC) staining on archival tissues of patients with non-small-cell lung cancer (NSCLC) was used to detect a panel of biomarkers, including phospho-ERK1/2, phospho-AKT, and E-cadherin, which are relevant to downstream signaling of CXCR4 and epithelial to mesenchymal transition (EMT)...
December 22, 2016: Clinical Lung Cancer
journal
journal
34772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"